Cartesian Therapeutics (RNAC) Share-based Compensation (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 3.39% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $759000.0, a 90.09% decrease from a year earlier, with the FY2025 full-year figure at $844000.0, down 87.18% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.4 million, up from -$7.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for RNAC reached as high as $3.8 million in Q2 2023 and fell as low as -$7.5 million in Q4 2025.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $2.3 million in 2023.
• Across the five-year window, Share-based Compensation soared 173.0% in 2022 and plunged 503.91% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $2.3 million in 2022, then sank by 402.28% to -$6.9 million in 2023, then surged by 127.11% to $1.9 million in 2024, then plunged by 503.91% to -$7.5 million in 2025, then jumped by 132.17% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.4 million in Q1 2026, -$7.5 million in Q4 2025, and $2.6 million in Q3 2025.